Table 1.
Major clinical trials of trreatments targeting the IL-23/IL-17 axis and their main efficacy and serious adverse events characteristics in patients with psoriatic arthritis.
| Agent | Biologic target | Trial | ACR50 Week12/16 |
ACR50 Week24 |
SAEs (%) | Reference |
|---|---|---|---|---|---|---|
| Ustekinumab | Anti-IL-12/23 p40 MoAb | PSUMMIT 1 Phase III |
90 mg 27.9% 45 mg 24.9% Placebo 8.7% |
1.5% 2% 2% |
McInnes et al., 2013 | |
| Ustekinumab | Anti-IL-12/23 p40 MoAb | PSUMMIT 2 Phase III |
90 mg 22.9% 45 mg 17.5% Placebo 6.7% |
1.9% 0% 4.8% |
Ritchlin et al., 2014 | |
| Guselkunab | Anti-IL-23 p19 MoAb | Phase II | 100 mg 34% Placebo 10% |
6% 0% |
Deodhar et al., 2018 | |
| Secukinumab | Anti-IL-17A MoAb | FUTURE-1 Phase III |
150 mg 34.7% 75 mg 30.7% Placebo 7.4% |
11.5% 7.4% 5% |
Mease et al., 2015 | |
| Secukinumab | Anti-IL-17A MoAb | FUTURE-2 Phase III |
300 mg 35% 150 mg 35% Placebo 7% Anti-TNFIR 300 mg 27% Anti-TNFIR 150 mg 19% Placebo 9% Anti-TNFnaive 300 mg 39% Anti-TNFnaive 150 mg 44% Placebo 6% |
6.4% 5.1% 8.6% |
McInnes et al., 2015 | |
| Secukinumab | Anti-IL-17A MoAb | FUTURE-5 Phase III |
300mg with loading dose 39.6% 150mg with loading dose 35.9% 150mg without loading dose 32% Placebo 8.1% |
3.2% 4.1% 2.7% 3.6% |
Mease et al., 2018b | |
| Ixekizumab | Anti-IL-17A MoAb | SPIRIT-P1 Phase III |
q2w:39.8% qw4:33.6% Placebo:4.7% Adalimuab:29.7% |
q2w:46.6% q4w:40.2% Adalimumab:38.6% |
q2w:4.9% q4w:3.7% Placebo:1.9% |
Mease et al., 2017b |
| Ixekizumab | Anti-IL-17A MoAb | SPIRIT-P2 Phase III |
q2w:33% q4w:35% placebo:5% |
Q2w:7% Q4w:3% Placebo:2% |
Nash et al., 2017 | |
| Brodalumab | Snti-IL17RA MoAb | Phase II | 140mg:14% 280mg:14% Placebo:4% |
140mg:2% 280mg:4% Placebo:2% |
Mease et al., 2014 |
IL-17RA, interleukin 17 receptor A; MoAb, monoclonal antibody; q2w, once every 2 weeks; q4w, once every 4 weeks; SAEs, serious advese events.